Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Equity

v3.10.0.1
Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
OPKO Health Europe
OPKO Renal
Transition Therapeutics, Inc.
Common Stock
Common Stock
OPKO Renal
Common Stock
Transition Therapeutics, Inc.
Treasury
Treasury
OPKO Health Europe
Additional Paid-In Capital
Additional Paid-In Capital
OPKO Health Europe
Additional Paid-In Capital
OPKO Renal
Additional Paid-In Capital
Transition Therapeutics, Inc.
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc.
Treasury
Xenetic Biosciences, Inc.
Additional Paid-In Capital
Beginning balance, shares (in shares) at Dec. 31, 2015         546,188,516     (1,120,367)                    
Beginning balance at Dec. 31, 2015 $ 1,957,695       $ 5,462     $ (3,645)   $ 2,705,385       $ (22,537) $ (726,970)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Equity-based compensation expense 42,693                 42,693                
Exercise of Common Stock options, shares (in shares)         3,292,753                          
Exercise of Common Stock options and warrants 8,608       $ 33         8,575                
Issuance of Common Stock in connection with acquisition (in shares)         51,235 2,611,648 6,431,899                      
Issuance of Common Stock in connection with acquisition 583   $ 25,986 $ 58,530 $ 1 $ 26 $ 64     582   $ 25,960 $ 58,466          
Issuance of Treasury Stock in connection with Contingent Consideration (in shares)                 39,145                  
Issuance of Treasury Stock in connection with Contingent Consideration   $ 313             $ 127   $ 186              
Issuance of shares (in shares)                                 494,462  
Issuance of shares                               $ 4,856 $ 1,607 $ 3,249
Net loss attributable to common shareholders (48,359)                           (48,359)      
Other comprehensive loss (4,472)                         (4,472)        
Ending balance, shares (in shares) at Dec. 31, 2016         558,576,051     (586,760)                    
Ending balance at Dec. 31, 2016 2,046,433       $ 5,586     $ (1,911)   2,845,096       (27,009) (775,329)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Equity-based compensation expense 28,307                 28,307                
Exercise of Common Stock options, shares (in shares)         1,447,694                          
Exercise of Common Stock options and warrants 2,132       $ 14         2,118                
Reclassification of embedded derivatives to equity 13,551                 13,551                
Issuance of Treasury Stock in connection with Contingent Consideration (in shares)                 36,853                  
Issuance of Treasury Stock in connection with Contingent Consideration   $ 304             $ 120   $ 184              
Net loss attributable to common shareholders (305,250)                           (305,250)      
Other comprehensive loss 26,481                         26,481        
Ending balance, shares (in shares) at Dec. 31, 2017         560,023,745     (549,907)                    
Ending balance at Dec. 31, 2017 1,843,623       $ 5,600     $ (1,791)   2,889,256       (528) (1,048,914)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Equity-based compensation expense $ 21,761                 21,761                
Exercise of Common Stock options, shares (in shares) 540,000       353,677                          
Exercise of Common Stock options and warrants $ 1,174       $ 4         1,170                
Issuance of shares (in shares)         26,504,298                          
Issuance of shares 92,500       $ 265         92,235                
Net loss attributable to common shareholders (153,040)                           (153,040)      
Other comprehensive loss (14,727)                         (14,727)        
Ending balance, shares (in shares) at Dec. 31, 2018         586,881,720     (549,907)                    
Ending balance at Dec. 31, 2018 $ 1,791,291       $ 5,869     $ (1,791)   $ 3,004,422       $ (20,131) $ (1,197,078)